This week we highlight a flood of studies and approvals with a focus on leveraging new technologies, data and gene sequencing to increase patient care. While the life sciences industry has always been on the forefront of innovation, we are now seeing the various components of the ecosystem come together to increase the efficiency and efficacy of discovery, ... READ MORE >
biopharma
5 things to know in life sciences: Week of September 27
Telehealth has been one of the big developments in health care brought on by the COVID-19 pandemic. It both promises to make care easier for patients to fit into their busy lives and holds the potential of allowing trials and new treatments to reach people far from the research hospitals in city centers. However, there are hurdles to overcome before much of ... READ MORE >
5 things to know in life sciences: Week of September 20
As the delta variant ravages communities throughout the Unites States, it is important to look past the data and remember that every infection, hospitalization and death leaves an indelible mark on that patient’s family and community. And few communities have suffered as much as Black communities in the South. This week we look at this tragedy—and the ... READ MORE >
5 things to know in life sciences: Week of July 19
This week, we explore an innovative artificial intelligence app used to treat mental health issues. We consider opportunities related to investments in women’s health. We also look at a few pharma giants, including two with a commitment to supply COVID-19 vaccines to Africa and one with a series of big wins and losses in its second-quarter earnings ... READ MORE >
5 things to know in life sciences: Week of June 28
Diabetes effects more than 10% of the U.S. population and brings with it the risk of serious complications, high health care costs and daily difficulties for patients that are afflicted with it. This week we look at the potential of using an old drug to help people with type 1 diabetes as well as the promise of a common tool used for type 1 patients to now ... READ MORE >
5 things to know in life sciences: Week of June 7
The U.S. Food and Drug Administration’s approval of the Alzheimer’s drug, aducanumab, ushered in both a likely blockbuster for developer Biogen and sparked a debate both within the biopharma industry and among health care providers. We also look at a major medical device acquisition, investment in synthetic biology, a White House report on supply chain risk, ... READ MORE >
5 things to know in life sciences: Week of May 31
Recruiting and retaining patients for clinical trials is one of the most intractable problems facing clinical research organizations and biopharma companies. CVS thinks that its thousands of retail locations could be the answer. We also look at Food and Drug Administration-approved video games, tracking patients using radar, drug manufacturing in the United ... READ MORE >
5 things to know in life sciences: Week of May 24
Over the past year, there has been a simmering dispute between hospitals and pharmaceutical companies over the 340B drug pricing program. This week, the United States Department of Health and Human Services weighed in strongly on the side of the hospitals. We also look at the discussion at the World Trade Organization on waiving intellectual property ... READ MORE >
5 things to know in life sciences: Week of May 17
While COVID-19 does not discriminate in infecting patients, the data actually shows that virus outcomes have disproportionately affected minority communities. Further, despite a focus on improving diversity in trials for the disease, the trials fell short of diversity goals. A new study looks at why and how biopharma companies can improve. This week we also ... READ MORE >
5 things to know in life sciences: Week of May 10
There are a few key milestones in the life cycle of a biopharma: raising your series A, starting your first clinical trial, going public and, for an increasing percent of companies, launching your first drug on your own. But developing a drug and successfully launching it requires different expertise and exposes the company to different risks. This week we ... READ MORE >